靶向穿刺遗漏:MRI靶向活检未能准确定位系统性穿刺所发现前列腺癌的预测因素
该回顾性研究纳入2014至2017年接受MRI/超声融合引导靶向穿刺联合系统性扩展六分区穿刺的患者,发现35/127(27.6%)患者靶向活检未能准确定位系统性穿刺检出的前列腺癌。较低MRI病灶体积(p=0.022)、病灶密度(p<0.001)和PI-RADS评分(p<0.001)与靶向活检遗漏癌显著相关。临床显著癌被遗漏罕见,多数遗漏为配准错误或邻近低级别癌。
要点
- 27.6%患者靶向活检未能准确定位系统性穿刺所检出的前列腺癌。
- 较低MRI病灶体积、病灶密度和PI-RADS评分是靶向遗漏的预测因素。
- 临床显著癌遗漏仅占总体5.5%,建议对MRI靶区及相邻六分区行系统采样。
核心结论
- MRI/超声融合引导靶向活检罕见遗漏临床显著前列腺癌,多数遗漏为配准错误或邻近六分区的低级别癌。
- 较低MRI病灶体积、病灶密度和PI-RADS评分可预测靶向活检遗漏系统性穿刺所检出的前列腺癌。
研究设计与样本
- 回顾性综述2014至2017年接受MRI/超声融合引导靶向穿刺联合同期系统性扩展六分区穿刺的患者。
- 对系统性穿刺检出前列腺癌而靶向活检未准确定位的患者,计算MRI靶病灶至癌阳性六分区的距离并评估预测参数。
主要发现
- 35/127(27.6%)患者靶向活检未能准确定位系统性穿刺检出的前列腺癌。
- 15/35(42.9%)为可能的融合软件配准错误,12/35(34.3%)靶向穿刺距癌灶一个六分区,8/35(22.9%)距癌灶两个六分区。
- 仅7/35(20.0%)患者为临床显著前列腺癌,占总体7/127(5.5%)。
- 较低MRI病灶体积(p=0.022)、病灶密度(p<0.001)和PI-RADS评分(p<0.001)与靶向活检遗漏显著相关。
临床怎么用
- 对MRI靶区所在六分区及相邻六分区进行系统采样可最大化前列腺癌检出。
- MRI病灶体积小、密度低或PI-RADS评分较低时,应警惕靶向活检遗漏风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Magnetic resonance imaging (MRI)/ultrasound (US) fusion-guided biopsy has improved the ability to localize and detect prostate cancer (PCa) with efficiency surpassing systematic biopsy. Nevertheless, some patients have PCa missed using the MRI-targeted biopsy sampling alone. We aim to identify clinical and imaging parameters associated with cases where targeted biopsy did not detect PCa compared to systematic biopsy. METHODS: We conducted a retrospective review of patients who underwent MRI/US fusion-guided biopsy in addition to concurrent systematic, extended-sextant biopsy between 2014 and 2017. For patients with PCa detected on systematic biopsy not properly localized by MRI/US fusion-guided biopsy, the sextant distance from MRI-targeted lesion to the cancer-positive sextant was calculated and parameters potentially predicting this targeting miss were evaluated. RESULTS: In all, 35/127 (27.6%) patients with single-session MRI/US fusion-guided biopsy plus standard biopsy finding PCa had lesions incorrectly localized. Of these, 15/35 (42.9%) were identified as possible fusion-software misregistrations. The remainder, 12/35 (34.3%), represented targeted biopsies one sextant away from the cancer focus and 8/35 (22.9%) targeted biopsies two sextants away from the cancer focus. Only 7/35 (20.0%) patients were determined to have clinically significant PCa, which represents 7/127 (5.5%) of the overall population. Lower MRI lesion volumes (p = 0.022), lesion density (p < 0.001), and PI-RADS scores (p < 0.001) were significantly associated with targeted biopsy missing PCa detected on systematic biopsy. CONCLUSION: Clinically significant PCa is rarely missed utilizing MRI/US fusion-guided biopsy. With the majority of missed tumors representing targeting misregistrations or cases of low-grade cancer in sextants immediately adjacent to MRI suspicious lesions. Lower MRI lesion volumes, lesion density, and PI-RADS are predictors of cases with targeted biopsies missing cancer, for which systematic sampling of the sextants containing MRI targets and adjacent sextants would most optimize PCa detection.
引用
- Coker MA, Glaser ZA, Gordetsky JB, et al. Targets missed: predictors of MRI-targeted biopsy failing to accurately localize prostate cancer found on systematic biopsy. Prostate Cancer Prostatic Dis. 2018. PMID: 29988101. doi:10.1038/s41391-018-0062-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。